MTM Laboratories AG’s p16/Ki-67 Dual Immuno-Staining Identifies High-Grade Cervical Disease in ASC-US and LSIL with High Sensitivity and Specificity

Published: Mar 30, 2011

HEIDELBERG, Germany--(BUSINESS WIRE)--mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results. These are a group of patients currently poorly served by existing screening technologies, with too many referred for unnecessary colposcopy. The paper, which details the EEMAPS study results, has been published electronically in Cancer Cytopathology on March 25, 2011 ahead of print.

Back to news